Phased Array High Intensity Focused Ultrasound (HIFU) Technology

Investment or Collaboration

HIFU therapy utilises ultrasound energy to heat and destroy tumour tissue whilst leaving surrounding healthy tissue intact. Compared with other cancer treatments, HIFU application has the unique advantages of being non-invasive, capable of precise tumour targeting and is coupled with very few side effects. A phased array HIFU prototype is currently being developed, with the potential to treat significantly larger volumes of tissue than can be currently treated with existing HIFU technologies. This should result in dramatically reduced treatment times, and collateral damage making HIFU clinically and economically viable.

CRT is now seeking equity investment to move from successful ex vivo and in vivo studies to clinical proof-of-principle (and exit) over the next 24 months.

Contact: Dr Roisin NicAmhlaoibh, rnicamhlaoibh@CancerTechnology.com

Further details can be accessed here